Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 12:01 PM ET


Company Overview of Athenex

Company Overview

Athenex, a specialty oncology pharmaceutical company, focuses on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. It offers Oraxol, an oral formulation of paclitaxel that allows for the oral delivery of paclitaxel when combined with Hanmi Pharmaceutical’s absorption enhancer HM30181, a potent and selective P-glycoprotein (PGP) pump inhibitor. The company also provides Oratecan, an oral formulation of Irinotecan for oncology indications, such as colorectal cancers; KX01 (KX2-391), an orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization; and KX02 (KX2-361), a dual Src/pre-tubulin...

701 Ellicott Street

Buffalo, NY 14203

United States

Founded in 2003





Key Executives for Athenex

Chairman and Chief Executive Officer
Age: 54
Co-Founder and Chief Scientific Officer
Chief Operating Officer and Director
Age: 49
President of Quadpharma
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Athenex Key Developments

Athenex Announces Address Change

Athenex has moved its North American headquarters into the Conventus medical office and research building on the Buffalo Niagara Medical Campus.

Athenex to Build Two Drug-Making Plants in China

Athenex has reached an agreement to build two drug manufacturing and distribution plants in China. The government in the Banan District of China's Chongqing province has agreed to pay for the land and construction of the two factories, while Athenex will pay to outfit the plants. The government's capital investment in the project is likely to total $200 million for a 400,000-square-foot finished goods and distribution plant and a 120,000-square-foot plant to make active pharmaceutical ingredients. Athenex will spend $75 million on equipment. Work on the plants should begin early 2016. Athenex expects to employ 500 workers at the two factories, and likely will hire more.

Athenex is considering IPO

Athenex is considering an IPO, possibly on the Nasdaq stock exchange.

Similar Private Companies By Industry

Company Name Region
Nutrition 21, Inc. United States
Rapidscan Pharma Solutions, Inc. United States
Jennerex Biotherapeutics, Inc. United States
Somerset Pharmaceuticals, Inc. United States
Apricus Pharmaceuticals USA, Inc. United States

Recent Private Companies Transactions

August 27, 2015
Comprehensive Drug Enterprises Ltd. and Taihao and Polymed Therapeutics, Inc.
Private Placement
March 26, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Athenex, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at